NCT03161912View on ClinicalTrials.gov

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease

CompletedOBSERVATIONAL
Enrollment

2,481

Participants

Timeline

Start Date

November 24, 2017

Primary Completion Date

September 14, 2021

Study Completion Date

December 17, 2021

Conditions
Macular Edema
Interventions
DRUG

Aflibercept (Eylea, BAY86-5321)

As per the treating physicians discretion.

Trial Locations (11)

Unknown

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY